Clinical Trial Update: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adagrasib with pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy in untreated KRAS G12C mutant non-sq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)
• Chemotherapy (chemotherapy)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: RECRUITING